Arca Biopharma (ABIO +30%) soars today after announcing that a paper was published in the European Journal of Heart Failure which presented data demonstrating that patients with established atrial fibrillation who received ABIO's Gencaro had improvements in heart failure clinical endpoints. The data also showed that Gencaro made it more likely for patients to achieve ventricular rate control, and that Gencaro improved cardiovascular clinical endpoints for those patients who did achieve rate control.
Arca Biopharma (ABIO +30%) soars today after announcing that a paper was published in the...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs